t-dm1 vs. trastuzumab as adjuvant therapy for her2-positive breast cancer
Published 4 years ago • 535 plays • Length 3:29Download video MP4
Download video MP3
Similar videos
-
3:25
new data comparing adjuvant t-dm1 vs trastuzumab for her2 breast cancer
-
5:46
adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for her2-positive breast cancer
-
2:52
5-year correlative analysis of atempt: adjuvant t-dm1 vs paclitaxel trastuzumab for stage i her2 bc
-
4:26
dr. sara tolaney on adjuvant t-dm1 vs paclitaxel and trastuzumab for stage i her2 breast cancer
-
4:54
adjuvant t-dm1 for stage i her2 breast cancer
-
5:42
adjuvant t-dm1 for her 2 breast cancer: critical data from the katherine study
-
3:51
adjuvant t-dm1 therapy for early-stage her2 breast cancer
-
1:00
case study - 21 "breast cancer: causes, symptoms, and treatment l common cancer in women."
-
5:15
case review: t-dm1 for residual her2 breast cancer
-
0:56
t-dm1 as part of our standard of care with residual her 2 disease
-
1:20
updated results of destiny-breast03: t-dxd vs t-dm1 in metastatic her2 breast cancer
-
4:41
neoadjuvant trastuzumab and pertuzumab plus chemotherapy versus t-dm1 and pertuzumab in her2 breast
-
4:16
adjuvant treatment for stage i her2 breast cancer
-
4:33
upfront t-dm1 in her2-positive breast cancer
-
4:54
patient perspectives on t-dm1 vs paclitaxel/trastuzumab for her2 early breast cancer
-
1:25
dr. tolaney on the neoadjuvant therapy for her2-positive breast cancer
-
1:21
dr. louis weiner discusses the t-dm1 emilia trial for her2-positive breast cancer
-
1:01
dr. hamilton discusses challenges with approved treatments for her2-positive breast cancer
-
2:00
dr. esteva discusses t-dm1 in her2-positive breast cancer